![Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patients]()
Serum M2BPGi level is a novel predictive biomarker for the responses to pegylated interferon-α treatment in HBeAg-positive chronic hepatitis B patientsZhu, Ming-Yu; Chen, Pei-Zhan; Li, Jing; Yu, De-Min; Huang, Dao; Zhu, Xue-Juan; Han, Yue; Chen, Jie; Huang, Wei; Chen, Yong-Yan; Gong, Qi-Ming; Jiang, Jie-Hong; Zhang, Dong-Hua; Zhang, Yan; Zhang, Ji-Ming; Zhang, Xin-Xin · Journal of Medical Virology · 2017